japanes
enceph
viru
jev
member
flaviviru
genu
famili
flavivirida
prototyp
member
jev
serocomplex
also
includ
west
nile
viru
wnv
st
loui
enceph
viru
slev
murray
valley
enceph
viru
jev
transmit
human
mosquito
caus
agent
japanes
enceph
je
symptom
je
typic
includ
fever
headach
incapacit
manifest
also
usual
result
frequent
involv
neurolog
je
major
impact
public
health
eastern
southern
asia
caus
symptomat
case
death
recent
jev
expand
geograph
footprint
previous
nonendem
area
sever
billion
peopl
risk
je
repres
intern
emerg
diseas
concern
tropic
subtrop
region
two
jev
vaccin
use
differ
part
asia
howev
concern
efficaci
safeti
cost
avail
vaccin
continu
high
percentag
peopl
atrisk
region
remain
unvaccin
although
consider
research
ongo
date
effect
antivir
therapeut
avail
treat
je
phosphorodiamid
morpholino
oligom
pmo
singlestrand
dna
analogu
contain
nucleobas
dna
join
backbon
consist
morpholin
ring
phorphorodiamid
mechan
antisens
action
pmo
steric
block
complementari
facilit
entri
cell
argininerich
cellpenetr
peptid
cpp
conjug
pmo
produc
ppmo
consider
antivir
activ
document
ppmo
number
posit
negativestrand
rna
virus
cell
cultur
murin
experiment
flavirus
ppmo
shown
efficaci
inhibit
infect
wnv
jev
slev
dengu
virus
denv
cultur
addit
ppmo
shown
consider
antivir
activ
wnv
denv
mous
jev
genom
plussens
singlestrand
rna
kb
singl
open
read
frame
orf
flank
region
utr
orf
encod
amino
acid
polyprotein
subsequ
cleav
three
structur
seven
nonstructur
viral
mosquitoborn
flavivirus
requir
least
two
longrang
basepair
interact
complementari
sequenc
region
genom
effici
replic
upstream
aug
region
interact
involv
complementari
nucleotid
compon
locat
upstream
aug
region
compon
locat
nucleotid
end
jev
anoth
interact
occur
pair
complementari
nucleotid
cycliz
sequenc
cs
locat
code
sequenc
capsid
protein
nucleotid
end
genom
cycliz
sequenc
often
denot
conserv
sequenc
locat
nucleotid
end
flank
sequenc
form
region
nucleotid
highli
conserv
across
member
jev
dea
et
show
ppmo
design
je
serocomplex
region
effect
reduc
wnv
slev
jev
replic
vero
cell
ppmo
produc
enhanc
surviv
mice
challeng
usual
lethal
dose
wnv
yoo
et
recent
show
acid
pna
conjug
target
region
also
inhibit
jev
replic
babi
hamster
kidney
bhk
cell
extend
find
jev
variou
type
cultur
cell
mous
model
je
diseas
mice
administ
ppmo
protect
lethal
jev
challeng
porcin
stabl
kidney
ps
cell
ncc
india
grown
mem
minim
essenti
medium
supplement
fetal
bovin
serum
fb
antibiot
cocktail
gibco
vero
cell
atcc
usa
maintain
eagl
minim
essenti
medium
emem
supplement
fb
antibiot
cell
atcc
usa
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fb
mm
sodium
pyruv
nonessenti
amino
acid
antibiot
cell
obtain
dr
p
stahl
washington
univers
school
medicin
st
loui
mo
usa
grown
rpmi
medium
supplement
fb
antibiot
strain
jev
obtain
dr
igarashi
nagasaki
univers
japan
grown
balbc
mice
titrat
plaqu
assay
use
ps
cell
describ
ppmo
synthes
avi
biopharma
inc
usa
use
previous
describ
produc
ppmo
cpp
rxr
r
stand
arginin
x
acid
b
coval
conjug
end
pmo
ppmo
design
complementari
sequenc
jev
genom
shown
tabl
base
scrambl
ppmo
random
sequenc
gc
content
pscr
use
neg
control
throughout
studi
studi
ppmo
uptak
cultur
cell
carboxyfluorescein
conjug
end
pscr
produc
ppmo
sequenc
screen
blast
http
wwwncbinlmnihgovblast
primat
murin
mrna
sequenc
pscr
ppmo
addit
screen
flavivir
sequenc
ppmo
dissolv
steril
distil
water
concentr
mm
stock
store
ppmomedi
inhibit
jev
replic
studi
vero
cell
cell
seed
densiti
cellswel
tissu
cultur
plate
fresh
cultur
medium
contain
fb
differ
amount
ppmo
ad
h
later
cell
monolay
allow
incub
h
ppmo
remov
cell
rins
twice
cultur
medium
infect
jev
multipl
infect
moi
inoculum
remov
h
later
cell
rins
cultur
medium
fresh
medium
contain
fb
read
incub
carri
cultur
supernat
remov
indic
time
postinfect
pi
extracellular
viru
titr
determin
plaqu
assay
infect
treatment
carri
triplic
statist
signific
differ
viral
titr
determin
student
ttest
p
valu
consid
signific
cell
monolay
obtain
treat
ppmo
h
cell
wash
pb
visual
via
phase
contrast
fluoresc
microscopi
parallel
experi
cell
monolay
treat
trypsinedta
produc
singl
cell
suspens
analys
flow
cytometri
flow
cytomet
read
stain
unstain
cell
obtain
fifti
thousand
cell
per
read
count
analys
winmdi
softwar
modal
fluoresc
intens
mfi
repres
averag
three
read
determin
use
flowjo
softwar
tree
star
inc
oregon
usa
cytotox
ppmo
vero
cell
evalu
use
lactat
dehydrogenas
ldh
releas
cell
viabil
assay
kit
sigma
per
manufactur
protocol
briefli
cell
monolay
incub
ppmo
h
follow
wash
replenish
cultur
medium
ldh
assay
perform
h
later
assay
carri
triplic
condit
intend
mimic
antivir
assay
group
balbc
mice
n
inject
intracerebr
use
gaug
needl
pb
pb
contain
indic
amount
ppmo
everi
h
day
appar
toxic
ppmo
mice
evalu
clinic
observ
abnorm
behaviour
appear
includ
hunch
lethargi
appetit
loss
ruffl
fur
appar
weak
death
mice
observ
everi
h
throughout
cours
studi
group
balbc
mice
n
inject
intracerebr
left
brain
lobe
pb
pb
contain
indic
amount
ppmo
h
intracerebr
inject
lethal
dose
jev
pfu
side
head
follow
jev
infect
mice
receiv
ppmo
intracerebr
site
everi
h
next
day
mice
observ
daili
day
infect
mortal
statist
signific
differ
surviv
mice
differ
treatment
group
determin
logrank
test
p
valu
consid
signific
group
balbc
mice
n
inject
intracerebr
jev
treat
ppmo
describ
determin
level
jev
brain
mice
variou
treatment
group
brain
tissu
harvest
h
interv
follow
jev
inocul
tissu
homogen
suspens
mem
centrifug
filtersteril
jev
titr
determin
plaqu
format
ps
cell
minimum
detect
limit
plaqu
assay
pfuml
anim
studi
conduct
follow
approv
protocol
institut
anim
care
ethic
committe
four
differ
ppmo
design
jev
sequenc
use
studi
tabl
three
design
target
jev
one
sequenc
figur
design
bind
region
genom
rna
therebi
interfer
assembl
translat
preiniti
complex
occur
cap
target
sequenc
upstream
aug
initi
codon
includ
region
predict
jev
target
sequenc
span
aug
translat
initi
codon
well
major
portion
sequenc
ppmo
design
interfer
translat
initi
interact
design
target
highli
conserv
region
figur
therebi
interfer
viral
rna
synthesi
three
cell
line
differ
lineag
use
studi
vero
epitheli
neuron
macrophag
shown
figur
produc
robust
inhibit
viral
replic
three
cell
line
measur
h
pi
howev
consider
variat
extent
inhibit
differ
cell
line
observ
complet
inhibit
jev
replic
vero
cell
p
wherea
viru
replic
reduc
cell
p
cell
p
h
pi
viru
replic
inhibit
still
complet
vero
cell
p
increas
p
cell
sinc
cell
treat
infect
produc
littl
viru
time
controltr
cell
produc
increas
amount
viru
time
rel
level
inhibit
appear
higher
h
h
ppmo
also
produc
signific
inhibit
jev
replic
mostli
earli
phase
growth
measur
h
pi
evalu
viral
titr
h
pi
show
signific
inhibit
vero
cell
interestingli
jev
grew
higher
titr
measur
h
pi
cell
treat
vehicletr
cell
reason
appar
enhanc
viral
growth
clear
studi
report
similar
may
import
implic
therapeut
applic
ppmo
timepoint
cell
type
jev
titr
significantli
suppress
unaffect
pscr
ppmo
inhibit
jev
replic
dosedepend
manner
vero
cell
figur
evalu
h
pi
produc
complet
inhibit
jev
replic
concentr
respect
pscr
use
concentr
affect
viru
titr
cytotox
examin
uninfect
vero
cell
condit
antivir
experi
ldh
releas
cell
viabil
assay
show
highest
concentr
use
antivir
experi
produc
appar
cytotox
three
cell
type
use
studi
data
shown
antivir
experi
describ
differenti
antivir
efficaci
observ
ppmo
differ
cell
line
investig
differ
could
attribut
differenti
ppmo
uptak
differ
cell
line
variou
cell
type
incub
pscrfl
ppmo
analys
microscopi
flow
cytometri
fluoresc
microscopi
indic
markedli
differ
level
uptak
differ
cell
type
vero
cell
exhibit
consider
fluoresc
cell
figur
quantit
analysi
flow
cytometri
show
almost
cell
type
took
base
measur
fluoresc
intens
cell
show
maximum
ppmo
uptak
follow
vero
cell
cell
show
least
uptak
rel
quantit
term
ppmotreat
cell
show
increas
mfi
compar
untreat
cell
increas
mfi
case
vero
cell
cell
rel
low
uptak
observ
cell
may
explain
lower
antivir
effect
cell
howev
uptak
data
explain
higher
antivir
effect
observ
vero
cell
compar
cell
investig
mechan
effector
antisens
effect
oper
differ
cell
type
need
help
explain
differ
inhibit
observ
determin
toxic
profil
intracerebr
deliv
ppmo
uninfect
mice
inject
vari
dose
level
ppmo
h
interv
day
ppmo
toxic
evalu
daili
observ
abnorm
level
ruffl
fur
hunch
weak
death
mice
receiv
dose
mgkg
ppmo
show
appar
sign
toxic
wherea
half
mice
receiv
mgkg
dose
die
day
figur
mice
receiv
mgkg
higher
dose
ppmo
die
day
jev
neurotrop
viru
replic
activ
neuron
glia
astrocyt
mous
brain
administ
intracerebr
lead
high
level
mortal
suckl
mous
model
potenti
inhibit
jev
replic
mous
brain
investig
intracerebr
inject
ppmo
jev
test
antivir
activ
jev
vivo
mice
n
administ
intracerebr
inject
mgkg
pscr
ppmo
follow
h
later
infect
lethal
dose
jev
rout
mice
receiv
ppmo
vehicl
pb
jev
without
jev
includ
addit
control
group
inject
administ
everi
h
next
day
group
mortal
monitor
day
three
trial
dose
level
mgkg
ppmo
one
trial
mgkg
ppmo
carri
figur
show
infect
mice
treat
mgkg
surviv
vehicl
pscrtreat
mice
die
day
p
uninfect
mice
receiv
surviv
protect
appear
dose
depend
infect
mice
receiv
mgkg
surviv
challeng
experi
first
mgkg
dose
administ
h
jev
infect
subsequ
dose
everi
h
next
day
led
mice
surviv
data
shown
investig
enhanc
mice
surviv
afford
treatment
associ
direct
inhibit
jev
replic
viral
titr
brain
infect
mice
group
receiv
ppmo
pscr
ppmo
mgkg
ppmo
vehicl
shown
figur
determin
figur
show
jev
titr
approach
pfuml
vehicletr
mice
h
pi
increas
averag
pfuml
next
day
signific
differ
seen
viral
titr
vehicletr
pscrtreat
mice
remark
mice
treat
mgkg
dose
show
detect
jev
brain
detect
limit
jev
plaqu
assay
pfuml
effect
antivir
treatment
exist
je
patient
often
warrant
hospit
offer
support
care
nucleic
acidbas
intervent
je
face
mani
challeng
develop
one
exampl
case
je
victim
typic
suffer
seriou
symptom
diseas
primari
viraemia
point
chanc
viral
nucleic
aciddirect
drug
effect
would
much
reduc
nevertheless
sever
factor
encourag
us
carri
current
studi
je
often
occur
epidemiolog
tempor
defin
outbreak
usual
juli
august
initi
symptom
overlap
day
consid
impact
je
public
health
lack
effect
drug
treat
felt
ppmo
previous
show
consider
antivir
activ
jev
vero
warrant
explor
antivir
activ
demonstr
sever
type
technolog
reli
sequencespecif
target
viral
rna
indic
antisensemedi
strategi
consider
util
research
reagent
potenti
therapeut
also
possibl
prophylact
treatment
peopl
enter
region
jev
known
present
would
valu
ppmo
target
region
effect
four
antisens
ppmo
evalu
studi
singl
treatment
suppress
viral
replic
significantli
vero
cell
dose
shown
noncytotox
vivo
dose
regimen
shown
well
toler
uninfect
mice
significantli
improv
surviv
jevinfect
mice
greatli
suppress
viral
replic
brain
ppmo
treatment
produc
differ
level
antivir
activ
differ
cell
type
differenti
uptak
ppmo
simpl
explan
observ
produc
best
knockdown
jev
vero
cell
cell
show
best
ppmo
uptak
possibl
differ
intracellular
traffick
ppmo
cell
previou
result
indic
probabl
imped
viral
replic
interf
molecular
event
process
rna
synthesi
ppmo
block
region
diminish
translat
wnv
denv
report
ppmo
composit
ppmo
afford
consider
protect
murin
model
wnv
studi
uninfect
mice
could
toler
repeat
daili
intraperiton
dose
mgkg
ppmo
mgkg
dose
caus
loss
bodi
weight
day
enhanc
surviv
control
ppmotreat
mice
observ
author
conclud
compound
show
consider
promis
overal
toxic
would
need
lower
allow
higher
dose
henc
perhap
enhanc
surviv
observ
similar
pattern
studi
ppmo
produc
substanti
enhanc
surviv
reduc
viru
titr
brain
compar
control
administ
intracerebr
dose
mgkg
howev
ppmo
administr
uninfect
mice
mgkg
dose
produc
notic
ill
effect
mortal
peptid
compon
rxr
ppmo
gener
acknowledg
necessari
deliveri
therapeut
effect
level
pmo
cell
howev
peptid
attend
toxic
vivo
clearli
develop
peptid
compon
ppmo
result
wider
therapeut
window
system
dose
would
enhanc
util
ppmo
technolog
effort
appar
altern
possibl
formul
present
rxr
would
improv
pharmacolog
properti
approach
similar
studi
yoo
et
use
panel
hiv
tatlik
peptid
conjug
pna
target
wellconserv
flaviviru
sequenc
cell
cultur
studi
jev
like
ppmo
pna
interfer
product
protein
mrna
sequencespecif
steric
block
rna
mechan
action
found
tatpna
target
top
jev
effect
produc
reduct
infecti
viru
relatedli
kumar
et
show
intracerebr
inject
small
hairpin
rna
shrna
code
lentiviru
lipidcomplex
small
interf
rna
sirna
target
conserv
sequenc
envelopecod
rna
protect
mice
jev
wnv
infect
previous
demonstr
dnazym
target
nucleotid
repeat
sequenc
jev
deliv
intracerebr
protect
mice
lethal
jev
studi
togeth
indic
compound
target
viral
nucleic
acid
may
use
address
jev
infect
although
core
sequenc
flavivirus
thought
nucleotid
region
nucleotid
region
includ
highli
conserv
within
jev
denv
region
shown
provid
product
target
locat
ppmo
number
flavivirus
ppmo
sequenc
highli
conserv
member
denv
serocomplex
found
effect
antivir
activ
infect
region
sequenc
target
highli
conserv
member
jev
serocomplex
proven
protect
jev
wnv
infect
vivo
repres
candid
develop
panjev
serocomplex
antivir
agent
small
anim
model
jev
limit
util
young
mice
inocul
intracerebr
consist
propag
jev
brain
level
necessari
antivir
drug
screen
goal
studi
explor
whether
ppmo
could
provid
antivir
action
jev
infect
brain
obvious
intracerebr
inject
relev
rout
administr
human
therapeut
establish
ppmo
travers
barrier
howev
natur
infect
jev
replic
peripher
prior
invad
may
ppmo
treatment
could
reduc
peripher
viru
titr
level
amen
clearanc
immun
system
hope
studi
ppmo
made
altern
peptid
formul
older
jevinfect
mice
use
rout
administr
intracerebr
viru
ppmo
thoroughli
evalu
prophylact
postinfect
treatment
option
work
support
core
fund
provid
nation
institut
immunolog
depart
biotechnolog
govt
india
support
fund
pacif
northwest
region
center
excel
biodefens
emerg
infecti
diseas
previous
work
compani
manufactur
ppmo
use
report
author
none
declar
